Company / Working Capital
ROCKET PHARMACEUTICALS, INC. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$162.5M
FY2025
5-year range
$162.5M / $369.9M
FY2021-FY2025
Trend
-51.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 8 years, ranging from $163M in FY2025 to $455M in FY2020.
Based on SEC 10-K filings.
$163M in FY2025 with a 5-year CAGR of -18.6%.
Declined from $330M to $163M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -20.6%
- 5-Year CAGR
- -18.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -18.6%, indicating a declining trend.
- In FY2025, working capital decreased 51.8% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $162.5M | -51.8% |
| FY2024 | $337.5M | +2.4% |
| FY2023 | $329.7M | +1.5% |
| FY2022 | $324.9M | -12.2% |
| FY2021 | $369.9M | -18.7% |
| FY2020 | $454.7M | +57.1% |
| FY2019 | $289.4M | +49.4% |
| FY2018 | $193.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026